Celldex Therapeutics, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-258.8M | $-157.9M | $-141.4M | $-112.3M | $-70.5M | $-59.8M | $-50.9M | $-151.2M |
| Depreciation & Amortization | $3.4M | $3.2M | $3.0M | $2.9M | $3.1M | $3.9M | $4.9M | $3.6M |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | $0 | $0 | $224.0K |
| Stock-Based Compensation | $36.2M | $34.2M | $23.9M | $15.6M | $9.0M | $3.9M | $4.6M | $8.1M |
| Net Cash from Operating Activities | $-210.9M | $-157.8M | $-107.3M | $-103.7M | $-60.9M | $-40.4M | $-46.4M | $-75.2M |
| Investing Activities | ||||||||
| Capital Expenditures | $2.7M | $1.9M | $1.8M | $1.8M | $1.2M | $1.6M | $731.0K | $813.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $209.1M | $-290.1M | $-105.8M | $89.9M | $-216.2M | $-98.2M | $17.1M | $29.8M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $2.4M | $441.4M | $218.5M | $4.1M | $272.4M | $171.2M | $16.3M | $29.4M |
| Net Change in Cash | $515.0K | $-6.5M | $5.4M | $-9.7M | $-4.7M | $32.6M | $-13.1M | $-16.0M |
| Free Cash Flow | $-213.7M | $-159.7M | $-109.1M | $-105.6M | $-62.2M | $-42.0M | $-47.1M | $-76.0M |